P24
SOLSTICE Week 48 subgroup analysis: Impact of BMI on ALT normalization after successful viral control in participants with chronic hepatitis delta virus infection treated with elebsiran and tobevibart
A. Jucov, T. Asselah, A. Streinu-Cercel, E. Gane, H. Wedemeyer, P. Lampertico, P. Kennedy, M.A. Chattergoon, B.L. Bullard, C. Huang, R. Acosta, S. Chow, C. Hwang, C. Pilowa, T. Correll, K. Agarwal
P25
Efficacy and safety of elebsiran (VIR-2218) in combination with tobevibart (VIR-3434) or tobevibart alone in participants with chronic hepatitis delta virus infection: Week 96 endpoint results from the Phase 2 SOLSTICE trial
T. Asselah, A. Streinu-Cercel, A. Jucov , E. Gane , H. Wedemeyer, P. Lampertico, P. Kennedy, M.A. Chattergoon, B.L. Bullard, C. Huang, R. Acosta, C. Pilowa, T. Correll, K. Agarwal
